Comparing of bluebird bio Inc. (BLUE) and UroGen Pharma Ltd. (NASDAQ:URGN)

As Biotechnology companies, bluebird bio Inc. (NASDAQ:BLUE) and UroGen Pharma Ltd. (NASDAQ:URGN) are our subject to compare. And more specifically their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
bluebird bio Inc. 39.50M 187.77 523.83M -8.19 0.00
UroGen Pharma Ltd. 1.46M 565.46 62.03M -4.01 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 provides bluebird bio Inc. and UroGen Pharma Ltd.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
bluebird bio Inc. -1,326.15% -31.5% -26.6%
UroGen Pharma Ltd. -4,248.63% -60.6% -56.5%

Liquidity

bluebird bio Inc.’s Current Ratio is 13.1 while its Quick Ratio is 13.1. On the competitive side is, UroGen Pharma Ltd. which has a 12.4 Current Ratio and a 12.4 Quick Ratio. bluebird bio Inc. is better positioned to pay off short and long-term obligations compared to UroGen Pharma Ltd.

Analyst Recommendations

bluebird bio Inc. and UroGen Pharma Ltd. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
bluebird bio Inc. 0 2 5 2.71
UroGen Pharma Ltd. 0 0 0 0.00

The average price target of bluebird bio Inc. is $147.83, with potential upside of 9.00%.

Institutional & Insider Ownership

The shares of both bluebird bio Inc. and UroGen Pharma Ltd. are owned by institutional investors at 0% and 73.9% respectively. About 0.3% of bluebird bio Inc.’s share are owned by insiders. Competitively, UroGen Pharma Ltd. has 2.78% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
bluebird bio Inc. -16.88% -23.58% -30.98% -43.22% -39.16% -42.64%
UroGen Pharma Ltd. -7.61% -2.39% 6.61% -19.07% 15.41% 21.77%

For the past year bluebird bio Inc. had bearish trend while UroGen Pharma Ltd. had bullish trend.

Summary

On 7 of the 11 factors bluebird bio Inc. beats UroGen Pharma Ltd.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in RaÂ’anana, Israel.